Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAP NASDAQ:BYSI NASDAQ:IZTC NASDAQ:PYRGF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.06-10.5%$0.09$0.04▼$0.36$15.35M2.4957.14 million shs49.26 million shsBYSIBeyondSpring$1.44-4.6%$1.60$1.21▼$3.44$59.21M0.4123,981 shs26,356 shsIZTCInvizyne Technologies$9.75-2.3%$8.94$8.50▼$23.00$60.96MN/A37,647 shs10,980 shsPYRGFPyroGenesis Canada$0.30+1.8%$0.36$0.12▼$0.53$61.98M0.2655,455 shs9,341 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics0.00%0.00%0.00%0.00%-79.75%BYSIBeyondSpring0.00%-4.49%-12.87%-1.32%-12.09%IZTCInvizyne Technologies0.00%-5.43%+11.56%-6.25%-10.47%PYRGFPyroGenesis Canada0.00%+0.58%-24.25%+61.61%-9.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.06-10.5%$0.09$0.04▼$0.36$15.35M2.4957.14 million shs49.26 million shsBYSIBeyondSpring$1.44-4.6%$1.60$1.21▼$3.44$59.21M0.4123,981 shs26,356 shsIZTCInvizyne Technologies$9.75-2.3%$8.94$8.50▼$23.00$60.96MN/A37,647 shs10,980 shsPYRGFPyroGenesis Canada$0.30+1.8%$0.36$0.12▼$0.53$61.98M0.2655,455 shs9,341 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics0.00%0.00%0.00%0.00%-79.75%BYSIBeyondSpring0.00%-4.49%-12.87%-1.32%-12.09%IZTCInvizyne Technologies0.00%-5.43%+11.56%-6.25%-10.47%PYRGFPyroGenesis Canada0.00%+0.58%-24.25%+61.61%-9.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAPAdaptimmune Therapeutics 1.67Reduce$0.651,028.38% UpsideBYSIBeyondSpring 1.00SellN/AN/AIZTCInvizyne Technologies 0.00N/AN/AN/APYRGFPyroGenesis Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ADAP, BYSI, IZTC, and PYRGF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2026BYSIBeyondSpring Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAPAdaptimmune Therapeutics$178.03M0.09N/AN/A$0.05 per share1.16BYSIBeyondSpringN/AN/A$0.11 per share13.11($0.59) per shareN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/APYRGFPyroGenesis Canada$9.14M6.78N/AN/A($0.01) per share-30.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAPAdaptimmune Therapeutics-$70.81M-$0.65N/AN/AN/A-260.82%-163.73%-75.83%N/ABYSIBeyondSpring-$1.01M-$0.15N/AN/AN/AN/AN/A-12.39%5/12/2026 (Estimated)IZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AN/APYRGFPyroGenesis Canada-$21.12M-$0.05N/AN/AN/A-115.14%N/A-60.81%N/ALatest ADAP, BYSI, IZTC, and PYRGF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q4 2025BYSIBeyondSpring-$0.54N/AN/AN/A$8.77 millionN/A3/25/2026Q4 2025BYSIBeyondSpring-$0.54-$0.05+$0.49-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAPAdaptimmune TherapeuticsN/A1.521.29BYSIBeyondSpringN/A1.541.54IZTCInvizyne TechnologiesN/AN/AN/APYRGFPyroGenesis CanadaN/A0.600.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAPAdaptimmune Therapeutics31.37%BYSIBeyondSpring40.29%IZTCInvizyne TechnologiesN/APYRGFPyroGenesis Canada0.03%Insider OwnershipCompanyInsider OwnershipADAPAdaptimmune Therapeutics12.44%BYSIBeyondSpring29.31%IZTCInvizyne TechnologiesN/APYRGFPyroGenesis Canada47.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAPAdaptimmune Therapeutics490265.05 million232.08 millionOptionableBYSIBeyondSpring8041.12 million29.07 millionOptionableIZTCInvizyne Technologies296.25 millionN/AN/APYRGFPyroGenesis Canada90206.61 million96.34 millionNo DataADAP, BYSI, IZTC, and PYRGF HeadlinesRecent News About These CompaniesPyroGenesis Schedules 2026 First Quarter Financial Results and Business Update Conference CallMay 1, 2026 | globenewswire.comPyroGenesis Provides Corporate Update on NexGen™ Titanium Metal Powder StrategyApril 29, 2026 | globenewswire.comPyroGenesis Announces Appointment of Jean Mayer as Vice-President, Legal Affairs and Corporate SecretaryApril 28, 2026 | globenewswire.comPyroGenesis Produces Battery-Grade Graphite from Carbon Black Using Proprietary Plasma SystemApril 23, 2026 | globenewswire.comPyroGenesis Canada (NASDAQ:PYRGF) Shares Up 5.3% - Here's WhyApril 21, 2026 | marketbeat.comPyroGenesis Announces Fourth Quarter and Full Year 2025 ResultsMarch 30, 2026 | globenewswire.comPyroGenesis Announces Closing of Non-Brokered Private PlacementMarch 26, 2026 | globenewswire.comPyroGenesis Schedules 2025 Fiscal Year Financial Results and Business Update Conference CallMarch 23, 2026 | globenewswire.comPyroGenesis Announces Oversubscription of Non-Brokered Private PlacementMarch 11, 2026 | globenewswire.comPyroGenesis Announces $1 Million Non-Brokered Private PlacementMarch 9, 2026 | globenewswire.comPyroGenesis Confirms Successful Primary Test Campaign with Leading Battery RecyclerMarch 6, 2026 | theglobeandmail.comPyroGenesis Completes Plasma Torch System Build for Constellium, Commences Delivery and Installation PhaseMarch 6, 2026 | globenewswire.comPyroGenesis Confirms Third-Party Verification of Its Fumed Silica: Successfully Meets Major Requirement for Proposed Joint VentureFebruary 19, 2026 | markets.businessinsider.comPyroGenesis Confirms Third-Party Verification of Its Fumed Silica: Successfully Meets Major ...February 19, 2026 | caledonianrecord.comCPyroGenesis Confirms Additional Independent Verification of Its Fumed Silica Meeting Commercial Grade “150”February 3, 2026 | globenewswire.comPyroGenesis Signs Agreement with U.S. Defense Contractor to Jointly Pursue Chemical Weapon Destruction Contracts in SyriaJanuary 6, 2026 | globenewswire.comPyroGenesis Provides 90-Day Cancellation Notice to EarthGridDecember 23, 2025 | globenewswire.comPyroGenesis Delivers 3.5 Tonnes of Titanium Powder Under New Powder Supply Agreement with U.S. Minerals and Metal Technology CompanyDecember 15, 2025 | globenewswire.comPyroGenesis Signs Plasma-Based Contract With Leading Battery RecyclerDecember 11, 2025 | globenewswire.comPyroGenesis Announces "Fine Cut” Titanium Powder Contract with U.S. Additive Manufacturing CompanyDecember 10, 2025 | manilatimes.netMPyroGenesis Announces “Fine Cut” Titanium Powder Contract with U.S. Additive Manufacturing CompanyDecember 10, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADAP, BYSI, IZTC, and PYRGF Company DescriptionsAdaptimmune Therapeutics NASDAQ:ADAPAdaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.BeyondSpring NASDAQ:BYSI$1.44 -0.07 (-4.64%) Closing price 04:00 PM EasternExtended Trading$1.44 +0.01 (+0.35%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Invizyne Technologies NASDAQ:IZTC$9.75 -0.23 (-2.30%) As of 05/1/2026Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.PyroGenesis Canada NASDAQ:PYRGF$0.30 +0.01 (+1.80%) As of 02:16 PM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
